Company profile
Premier Biomedical, Inc.
OTC: BIEI · Healthcare · Medical - Pharmaceuticals
#1125 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ 13GM —SS 35
v0.1 · 25/100 weight · pillars only
↑ listing tenure, market scale · ↓ Piotroski F, Altman-Z
Methodology →Revenue TTM
$58.3k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$374.5k
Employees
4
as of 2026-08-26
Market cap
$780.0k
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$14.3k$14.3k2019
Net income-$374.5k-$374.5k2019
Operating income-$326.7k-$326.7k2019
Total assets$100.9k$100.9k2019
Liabilities$1.9M$1.9M2019
Equity-$1.8M-$1.8M2019
Revenue trend
FY2017 – FY2019 · USD
FY17
FY18
FY19
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Premier Biomedical, Inc.’s revenue?
Premier Biomedical, Inc. booked $14.3k in FY2019 revenue, contracting 64% year over year — slower than 85% of Healthcare companies we track, at a -2622.2% net margin.
Peers · Healthcare
Cardio Diagnostics Holdings, Inc.30DNavidea Biopharmaceuticals, Inc.——Nass Valley Gateway Ltd.——Wuhan General Group (China), Inc.——Cryomass Technologies Inc.——Relmada Therapeutics, Inc.38DKey facts
CEOIvan Mendez
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersKnoxville, PA
ExchangeOTC: BIEI
Employees4
IPO date2012-08-15
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.